Owing to its dispensable function under physiologicalconditions,ADAM8 has been considered a promising drug target for cancer therapy,whose inhibition could give fewer side effects than ADAM10/17 inhibitors.6 In particular, ADAM8 has been recently validatedas a drug target in pancreatic,7 liver,8 and breast cancer.9 Unfortunately, the development of potent and selective ADAM8 inhibitorshas been hampered by the high homology among matrix metalloproteinase(MMP) and ADAM catalytic sites. Here, ADAM8 is linked to breast carcinoma.